Ge Long Hui A P P·2025-10-16 10:03Core Viewpoint - The company, Buchang Pharma (603858.SH), has signed a technical service contract with WuXi AppTec for pharmacokinetics and toxicology testing, amounting to 10.8 million yuan, which will enhance its drug development capabilities and reduce clinical trial time and costs [1] Group 1 - The contract total is 10.8 million yuan, including a 6% tax [1] - The agreement allows for phased payments as per the contract terms [1] - Collaborating with a third party like WuXi AppTec is expected to expand the company's drug research and development capacity [1] Group 2 - The partnership is anticipated to save time and costs associated with clinical trials [1] - The project is expected to proceed smoothly due to the support from WuXi AppTec [1]